Massive study pits semaglutide against dulaglutide to protect hearts in diabetes
NCT ID NCT07619495
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at health records of 120,000 people with type 2 diabetes and overweight to compare two injectable drugs: semaglutide and dulaglutide. Researchers want to see which one better reduces the risk of death, heart attack, or stroke. The goal is to understand how these drugs work in real-world settings, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide and dulaglutide (injectable diabetes medications)
What this could lead to
If successful, this could show which drug is more effective at preventing heart attacks, strokes, or death in people with type 2 diabetes and overweight.
What could go wrong
This is an observational study using existing health records, not a controlled trial, so results may be less reliable. It also does not test a new treatment, just compares two existing drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States